Leukemia Posts on Medivizor

Can oral azacitidine maintenance promote longer survival in older patients with acute myeloid leukemia in first remission following chemotherapy?

Posted by Medivizor on May 28, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness of oral azacitidine (Onureg; Oral-AZA) maintenance treatment in older patients with acute myeloid leukemia (AML) in remission. The data showed that Oral-AZA maintenance therapy can be considered in older patients with AML for which hematopoietic stem cell transplantation (HSCT) is not an...

Is an alternative, chemotherapy-free approach possible for patients with acute promyelocytic leukemia?

Posted by Medivizor on Apr 30, 2023 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness of treatment with all-trans retinoic acid (ATRA; Retin-a) and arsenic trioxide (ATO; Trisenox) to ATRA-ATO with chemotherapy (CHT) in patients with newly diagnosed acute promyelocytic leukemia (APL). The data showed that treatment with ATRA-ATO was equally effective as ATRA-ATO plus CHT in these...

Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.

Posted by Medivizor on Apr 23, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of asciminib (Scemblix) in real-world patients with chronic myeloid leukemia (CML) previously treated with ponatinib (Iclusig). The data showed that asciminib treatment had promising effectiveness in these patients. Some background CML is a type of cancer that starts in blood-forming...

Can BCT-100 be safely combined with low-dose cytarabine for older patients with acute myeloid leukemia that cannot receive intensive therapy?

Posted by Medivizor on Apr 15, 2023 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness and safety of low-dose (LD) cytarabine (Ara-C; Cytosar-U) with recombinant arginase BCT-100 (BCT-100) to Ara-C alone in older patients with acute myeloid leukemia (AML) that were unsuitable for intensive therapy. The data showed that LD Ara-C (LDAC) combined with BCT-100 resulted in similar...

How does inotuzumab ozogamicin influence time to first subsequent salvage therapy in patients with relapsed or refractory acute lymphoblastic leukemia?

$How does inotuzumab ozogamicin influence time to first subsequent salvage therapy in patients with relapsed or refractory acute lymphoblastic leukemia?$

Posted by Medivizor on Mar 26, 2023 in Leukemia | 0 comments

In a nutshell This study analyzed the effect of inotuzumab ozogamicin (InO; Besponsa) treatment on time to subsequent salvage therapy (TST) in patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL). The data showed that TST was longer with InO compared to standard of care (SoC) treatment. Some background Salvage...

Evaluating the effectiveness and safety of busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for patients with adult B-cell acute lymphoblastic leukemia.

Posted by Medivizor on Mar 26, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of busulfan (Bu; Busulfex) plus cyclophosphamide (Cy; Cytoxan) (BuCy) regimen versus total body irradiation (TBI) plus cyclophosphamide (TBI-Cy) regimen for patients with adult B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission undergoing allogeneic hematopoietic...

Evaluating the safety and effectiveness of ibrutinib lead-in treatment before venetoclax initiation in reducing tumor size in patients with chronic lymphocytic leukemia.

Posted by Medivizor on Mar 16, 2023 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) lead-in treatment before venetoclax (Venclexta) initiation for reducing tumor size in patients with chronic lymphocytic leukemia (CLL). The data showed that three cycles of ibrutinib lead-in treatment before venetoclax initiation significantly reduced the tumor...

Evaluating the effectiveness and safety of gilteritinib plus azacitidine versus azacitidine alone for patients with newly diagnosed FLT3-mutated acute myeloid leukemia.

Posted by Medivizor on Feb 28, 2023 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of gilteritinib (Xospata) plus azacitidine (Vidaza) versus azacitidine alone for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. The data showed that gilteritinib plus azacitidine...

Evaluating the benefits of allogeneic hematopoietic stem cell transplantation in childhood acute myeloid leukemia.

Posted by Medivizor on Feb 5, 2023 in Leukemia | 0 comments

In a nutshell This study analyzed the use of allogeneic hematopoietic stem cell transplantation (alloHSCT) therapy following first remission in children with newly diagnosed, high-risk acute myeloid leukemia (AML) compared to chemotherapy. This study supports the use of alloHSCT for children with AML that are at greater. Some background Childhood AML...

Evaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation.

$Evaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation.$

Posted by Medivizor on Jan 8, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the tolerability and effectiveness of combined therapy using venetoclax (Venclexta) and gilteritinib (Xospata) in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) with the FLT3 (FMS-related tyrosine kinase 3) mutation. The data showed that a combination of venetoclax and gilteritinib potentially...

Evaluating treosulfan vs reduced-intensity busulfan conditioning for allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia

Posted by Medivizor on Dec 31, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of allogeneic hematopoietic cell transplant (alloHCT) for older patients with acute myeloid leukemia (AML) using treosulfan (Trecondi) compared to reduced intensity busulfan (Myleran) conditioning. This study concluded that treosulfan conditioning appears to be more suitable for...

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Posted by Medivizor on Dec 31, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of zanubrutinib (Brukinsa) versus bendamustine (Treanda) plus rituximab (Rituxan) in untreated patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data showed that zanubrutinib significantly improved the survival without cancer worsening versus...

Leukemia Posts on Medivizor

Can oral azacitidine maintenance promote longer survival in older patients with acute myeloid leukemia in first remission following chemotherapy?

Is an alternative, chemotherapy-free approach possible for patients with acute promyelocytic leukemia?

Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.

Can BCT-100 be safely combined with low-dose cytarabine for older patients with acute myeloid leukemia that cannot receive intensive therapy?

How does inotuzumab ozogamicin influence time to first subsequent salvage therapy in patients with relapsed or refractory acute lymphoblastic leukemia?

Evaluating the effectiveness and safety of busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for patients with adult B-cell acute lymphoblastic leukemia.

Evaluating the safety and effectiveness of ibrutinib lead-in treatment before venetoclax initiation in reducing tumor size in patients with chronic lymphocytic leukemia.

Evaluating the effectiveness and safety of gilteritinib plus azacitidine versus azacitidine alone for patients with newly diagnosed FLT3-mutated acute myeloid leukemia.

Evaluating the benefits of allogeneic hematopoietic stem cell transplantation in childhood acute myeloid leukemia.

Evaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation.

Evaluating treosulfan vs reduced-intensity busulfan conditioning for allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Categories

Recent Posts

Archives

Leukemia Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email